News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
40 Under 40
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
40 Under 40
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
699,365 Results
Type
Article (39768)
Company Profile (254)
Press Release (659343)
Multimedia
Podcasts (49)
Webinars (12)
Section
Business (204362)
Career Advice (2011)
Deals (35444)
Drug Delivery (95)
Drug Development (81135)
Employer Resources (172)
FDA (16188)
Job Trends (14873)
News (345499)
Policy (32558)
Tag
Academia (2555)
Accelerated approval (5)
Adcomms (21)
Allergies (85)
Alliances (49502)
ALS (89)
Alzheimer's disease (1378)
Antibody-drug conjugate (ADC) (128)
Approvals (16191)
Artificial intelligence (253)
Autoimmune disease (21)
Automation (16)
Bankruptcy (360)
Best Places to Work (11645)
BIOSECURE Act (19)
Biosimilars (105)
Biotechnology (182)
Bladder cancer (77)
Brain cancer (27)
Breast cancer (278)
Cancer (2259)
Cardiovascular disease (174)
Career advice (1678)
Career pathing (30)
CAR-T (151)
Cell therapy (422)
Cervical cancer (19)
Clinical research (66047)
Collaboration (836)
Compensation (529)
Complete response letters (19)
COVID-19 (2594)
CRISPR (40)
C-suite (241)
Cystic fibrosis (100)
Data (2198)
Decentralized trials (2)
Denatured (18)
Depression (42)
Diabetes (270)
Diagnostics (6371)
Digital health (18)
Diversity (8)
Diversity, equity & inclusion (44)
Drug discovery (120)
Drug pricing (98)
Drug shortages (25)
Duchenne muscular dystrophy (93)
Earnings (86634)
Editorial (36)
Employer branding (21)
Employer resources (146)
Events (112522)
Executive appointments (722)
FDA (17440)
Fibrodysplasia Ossificans Progressiva (1)
Friedreich's ataxia (4)
Frontotemporal dementia (7)
Funding (750)
Gene editing (104)
Generative AI (19)
Gene therapy (304)
GLP-1 (707)
Government (4415)
Grass and pollen (4)
Guidances (62)
Healthcare (18830)
Huntington's disease (23)
IgA nephropathy (27)
Immunology and inflammation (116)
Indications (29)
Infectious disease (2736)
Inflammatory bowel disease (137)
Inflation Reduction Act (8)
Influenza (51)
Intellectual property (96)
Interviews (312)
IPO (16518)
IRA (40)
Job creations (3639)
Job search strategy (1424)
Kidney cancer (10)
Labor market (38)
Layoffs (467)
Leadership (17)
Legal (7911)
Liver cancer (75)
Lung cancer (320)
Lymphoma (155)
Machine learning (7)
Management (58)
Manufacturing (303)
MASH (66)
Medical device (13377)
Medtech (13382)
Mergers & acquisitions (19468)
Metabolic disorders (682)
Multiple sclerosis (80)
NASH (16)
Neurodegenerative disease (89)
Neuropsychiatric disorders (27)
Neuroscience (1912)
NextGen: Class of 2025 (6523)
Non-profit (4481)
Now hiring (39)
Obesity (362)
Opinion (204)
Ovarian cancer (76)
Pain (89)
Pancreatic cancer (83)
Parkinson's disease (148)
Partnered (21)
Patents (233)
Patient recruitment (110)
Peanut (46)
People (57366)
Pharmaceutical (63)
Pharmacy benefit managers (18)
Phase I (20585)
Phase II (29087)
Phase III (21663)
Pipeline (1192)
Policy (138)
Postmarket research (2564)
Preclinical (8751)
Press Release (64)
Prostate cancer (106)
Psychedelics (30)
Radiopharmaceuticals (246)
Rare diseases (380)
Real estate (5920)
Recruiting (65)
Regulatory (22300)
Reports (46)
Research institute (2321)
Resumes & cover letters (350)
Rett syndrome (5)
RNA editing (5)
RSV (42)
Schizophrenia (68)
Series A (130)
Series B (85)
Service/supplier (11)
Sickle cell disease (52)
Special edition (14)
Spinal muscular atrophy (147)
Sponsored (29)
Startups (3583)
State (2)
Stomach cancer (13)
Supply chain (68)
Tariffs (39)
The Weekly (29)
Vaccines (685)
Venture capitalists (41)
Weight loss (234)
Women's health (35)
Worklife (16)
Date
Today (169)
Last 7 days (865)
Last 30 days (2645)
Last 365 days (32898)
2025 (10653)
2024 (35252)
2023 (40104)
2022 (51230)
2021 (55762)
2020 (54123)
2019 (46565)
2018 (35041)
2017 (32144)
2016 (31522)
2015 (37590)
2014 (31361)
2013 (26382)
2012 (28585)
2011 (29284)
2010 (27353)
Location
Africa (718)
Alabama (53)
Alaska (7)
Arizona (231)
Arkansas (13)
Asia (37914)
Australia (6207)
California (6119)
Canada (2011)
China (523)
Colorado (266)
Connecticut (274)
Delaware (147)
Europe (81369)
Florida (908)
Georgia (206)
Idaho (57)
Illinois (534)
India (25)
Indiana (306)
Iowa (11)
Japan (161)
Kansas (104)
Kentucky (23)
Louisiana (10)
Maine (62)
Maryland (893)
Massachusetts (4559)
Michigan (220)
Minnesota (392)
Mississippi (2)
Missouri (81)
Montana (27)
Nebraska (25)
Nevada (63)
New Hampshire (63)
New Jersey (1723)
New Mexico (28)
New York (1738)
North Carolina (967)
North Dakota (8)
Northern California (2676)
Ohio (203)
Oklahoma (14)
Oregon (34)
Pennsylvania (1386)
Puerto Rico (12)
Rhode Island (33)
South America (1096)
South Carolina (22)
South Dakota (1)
Southern California (2293)
Tennessee (101)
Texas (906)
United States (23085)
Utah (180)
Virginia (144)
Washington D.C. (61)
Washington State (551)
West Virginia (3)
Wisconsin (54)
699,365 Results for "latigo biotherapeutics inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Latigo Biotherapeutics Closes $150 Million in Series B Financing to Advance Non-Opioid Pain Therapeutics
March 17, 2025
·
3 min read
Press Releases
Latigo Biotherapeutics Granted FDA Fast Track Designation for LTG-001, Potential Best-in-Class Nav1.8 Inhibitor for the Non-Opioid Treatment of Acute Pain
March 4, 2025
·
3 min read
Press Releases
Latigo Biotherapeutics Appoints Industry Veteran Timothy P. Walbert as Board Chair
November 19, 2024
·
3 min read
Biotech Beach
Latigo Biotherapeutics Debuts with $135 Million Series A Financing to Develop Non-Opioid Pain Medicines
Latigo Biotherapeutics Inc., a clinical-stage biotechnology company developing best-in-class non-opioid pain medicines that target pain at its source, announced its emergence from stealth with a $135 million Series A financing.
February 14, 2024
·
3 min read
Press Releases
Latigo Biotherapeutics Doses First Participant in Phase 1 Clinical Trial of LTG-305 for Non-Opioid Treatment of Pain
October 17, 2024
·
3 min read
Press Releases
Latigo Biotherapeutics Appoints Tim Lugo as Chief Financial Officer and Adds Beth Seidenberg and Jim Tananbaum to Board of Directors
September 9, 2024
·
6 min read
Press Releases
Latigo Biotherapeutics Appoints Nima Farzan as Chief Executive Officer, Positioning Company for Rapid Growth
July 22, 2024
·
3 min read
Latigo Launches into Non-Opioid Pain Medicine Space with $135 Million Series A
Two weeks after Vertex’s Phase III data for VX-548 reenergized the field, Latigo Biotherapeutics announced $135 million in Series A funds to push its own NaV1.8 inhibitor into Phase II.
February 13, 2024
·
3 min read
·
Heather McKenzie
Press Releases
Latigo Biotherapeutics Announces Positive Phase 1 Data for Lead Non-Opioid Pain Medicine Candidate and Appoints Neil Singla, M.D., Chief Medical Officer
August 19, 2024
·
5 min read
Antibody-drug conjugate (ADC)
Roche Ups ADC Bet With $1B in Biobucks for Oxford BioTherapeutics
Roche’s up to $1 billion investment will provide access to Oxford BioTherapeutics’ antibody-drug conjugate platform for undisclosed cancer targets.
March 19, 2025
·
1 min read
·
Tristan Manalac
1 of 69,937
Next
